Invivyd Inc. (NASDAQ:IVVD) is one of the best NASDAQ growth stocks to buy and hold forever. On April 9, Invivyd announced ...
--Invivyd, Inc., today announced full Phase 1/ 2 clinical data for VYD2311, a next-generation monoclonal antibody candidate designed to prevent and treat COVID-19. VYD2311 builds on the success of ...
Invivyd reported Q4 2024 revenue of $13.8 million, highlighting significant growth and ongoing development of COVID-19 treatments PEMGARDA and VYD2311. Invivyd, Inc. reported a net product revenue of ...
WALTHAM, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced ...
ATLANTA, GA - (NewMediaWire) - June 27, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced ...
CAMBRIDGE, Mass. — Moderna said on Tuesday its updated COVID-19 vaccine formulation elicited a strong immune response in all adults aged 65 and older, as well as in individuals aged 12-64 with at ...
Hosted on MSN
FDA approves Moderna’s next-generation COVID-19 vaccine: Here's what makes it different
CHENNAI: The US Food and Drug Administration (FDA) on Saturday officially approved Moderna’s next-generation COVID-19 vaccine for use in key high-risk populations. This marks the first FDA endorsement ...
In a recent study published in the journal PNAS, a group of researchers developed an intranasal measles-mumps-SARS-CoV-2 spike (S) protein (MMS) vaccine that offers broad, durable protection against ...
NEW BRUNSWICK, N.J. -- Booster doses of Johnson & Johnson's one-shot coronavirus vaccine generated a big spike in antibodies, the frontline immune system defenses against infection, the company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results